Editorial: Developing an asymptomatic mucosal herpes vaccine: The present and the future

Future Microbiology

Volumn 5, Issue 1, 2010, Pages 1-4

  Dasgupta, Gargi ^a   Nesburn, Anthony B ^a   Wechsler, Steven L ^a   BenMohamed, Lbachir ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ACICLOVIR DERIVATIVE; EPITOPE; HERPES VACCINE; LIVE VACCINE; NAKED DNA; NUCLEOSIDE DERIVATIVE; SUBUNIT VACCINE;

CD8+ T LYMPHOCYTE; CLINICAL TRIAL; DNA REPLICATION; EDITORIAL; ENCEPHALITIS; EYE DISEASE; GENE EXPRESSION; GENITAL HERPES; GENITAL ULCER; HERPES SIMPLEX VIRUS; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HERPES VIRUS INFECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOGENICITY; MUCOSAL DISEASE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; VERTICAL TRANSMISSION; VIRUS REACTIVATION; HERPES SIMPLEX; IMMUNOLOGY; MEDICAL RESEARCH; MUCOSAL IMMUNITY;

HERPES;

BIOMEDICAL RESEARCH; HERPES SIMPLEX; HERPESVIRUS VACCINES; HUMANS; IMMUNITY, MUCOSAL; T-LYMPHOCYTES;

EID: 75949090236     PISSN: 17460913     EISSN: None     Source Type: Journal    
DOI: 10.2217/fmb.09.101     Document Type: Editorial

References (33)

1. Dasgupta G, Chentoufi AA, Nesburn AB, Wechsler SL, BenMohamed L: New concepts in herpes simplex virus vaccine development: notes and challenges from the battlefield. Expert Rev. Vaccines 8(8), 426-437 (2009).
2. Divito S, Cherpes TL, Hendricks RL: A triple entente: virus, neurons, and CD8+ T cells maintain HSV-1 latency. Immunol. Res. 36(1-3), 119-126 (2006).
3. BenMohamed L, Belkaid Y, Loing E, Brahimi K, Gras-Masse H, Druilhe P: Systemic immune responses induced by mucosal administration of lipopeptides without adjuvant. Eur. J. Immunol. 32(8), 2274-2281 (2002).
4. BenMohamed L, Krishnan R, Auge C, Primus JF, Diamond DJ: Intranasal administration of a synthetic lipopeptide without adjuvant induces systemic immune responses. Immunology 106(1), 113-121 (2002).
5. BenMohamed L, Wechsler SL, Nesburn AB: Lipopeptide vaccines - yesterday, today, and tomorrow. Lancet Infect. Dis. 2(7), 425-431 (2002).
6. Perng GC, Maguen B, Jin L et al.: A novel herpes simplex virus type 1 transcript (AL-RNA) antisense to the 5́ end of the latency-associated transcript produces a protein in infected rabbits. J. Virol. 76(16), 8003-8010 (2002).
7. BenMohamed L, Bertrand G, McNamara CD et al.: Identification of novel immunodominant CD4+ Th1-type T-cell peptide epitopes from herpes simplex virus glycoprotein D that confer protective immunity. J. Virol. 77(17), 9463-9473 (2003).
8. Vichier-Guerre S, Lo-Man R, BenMohamed L et al.: Induction of carbohydrate-specific antibodies in HLA-DR transgenic mice by a synthetic glycopeptide: a potential anti cancer vaccine for human use. J. Pept. Res. 62(3), 117-124 (2003).
9. Zhang X, Issagholian A, Berg EA, Fishman JB, Nesburn AB, BenMohamed L: Th cytotoxic T-lymphocyte chimeric epitopes extended by Ne-palmitoyl lysines induce herpes simplex virus type 1-specific effector CD8+ Tc1 responses and protect against ocular infection. J. Virol. 79(24), 15289-15301 (2005).
10. Zhu X, Ramos TV, Gras-Masse H, Kaplan BE, BenMohamed L: Lipopeptide epitopes extended by an Ne-palmitoyl-lysine moiety increase uptake and maturation of dendritic cells through a Toll-like receptor-2 pathway and trigger a Th1-dependent protective immunity. Eur. J. Immunol. 34(11), 3102-3114 (2004).
11. Corey L, Langenberg AG, Ashley R et al.: Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine study group. JAMA 282(4), 331-340 (1999).
12. Langenberg AG, Corey L, Ashley RL, Leong WP, Straus SE: A prospective study of new infections with herpes simplex virus type 1 and type 2. Chiron HSV Vaccine study group. N. Engl. J. Med. 341(19), 1432-1438 (1999).
13. Whitley RJ, Miller RL: Immunologic approach to herpes simplex virus. Viral Immunol. 14(2), 111-118 (2001).
14. Whitley RJ, Roizman B: Herpes simplex virus infections. Lancet 357(9267), 1513-1518 (2001).
15. Weiss H: Epidemiology of herpes simplex virus type 2 infection in the developing world. Herpes 11(Suppl. 1), 24A-35A (2004).
16. Dana MR, Qian Y, Hamrah P: Twenty-five-year panorama of corneal immunology: emerging concepts in the immunopathogenesis of microbial keratitis, peripheral ulcerative keratitis, and corneal transplant rejection. Cornea 19(5), 625-643 (2000).
17. Koelle DM, Corey L: Recent progress in herpes simplex virus immunobiology and vaccine research. Clin. Microbiol. Rev. 16(1), 96-113 (2003).
18. Koelle DM, Liu Z, McClurkan CL et al.: Immunodominance among herpes simplex virus-specific CD8 T cells expressing a tissue-specific homing receptor. Proc. Natl Acad. Sci. USA 100(22), 12899-12904 (2003).
19. Mancini-Bourgine M, Bayard F, Soussan P et al.: Hepatitis B virus splice-generated protein induces T-cell responses in HLA-transgenic mice and HBV-infected patients. J. Virol. 81(10), 4963-4972 (2007).
20. Nagot N, Ouedraogo A, Foulongne V et al.: Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus. N. Engl. J. Med. 356(8), 790-799 (2007).
21. Nesburn AB, Bettahi I, Zhang X et al.: Topical/mucosal delivery of sub-unit vaccines that stimulate the ocular mucosal immune system. Ocul. Surf. 4(4), 178-187 (2006).
22. Smith E, Hallman JR, Pardasani A, McMichael A: Multiple herpetic whitlow lesions in a patient with chronic lymphocytic leukemia. Am. J. Hematol. 69(4), 285-288 (2002).
23. Chentoufi AA, Binder NR, Berka N et al.: Asymptomatic human CD4+ cytotoxic T-cell epitopes identified from herpes simplex virus glycoprotein B. J. Virol. 82(23), 11792-11802 (2008).
24. Chentoufi AA, Zhang X, Lamberth K et al.: HLA-A*0201-restricted CD8+ cytotoxic T lymphocyte epitopes identified from herpes simplex virus glycoprotein D. J. Immunol. 80(1), 426-437 (2008).
25. Bettahi I, Dasgupta G, Renaudet O et al.: Antitumor activity of a self-adjuvanting glyco-lipopeptide vaccine bearing B cell, CD4+ and CD8 + T cell epitopes. Cancer Immunol. Immunother. 58(2), 187-200 (2009).
26. Abu-Raddad LJ, Magaret AS, Celum C et al.: Genital herpes has played a more important role than any other sexually transmitted infection in driving HIV prevalence in Africa. PLoS ONE 3(5), e2230 (2008).
27. Oram RJ, Marcellino D, Strauss D et al.: Characterization of an acyclovir-resistant herpes simplex virus type 2 strain isolated from a premature neonate. J. Infect. Dis. 181(4), 1458-1461 (2000).
28. Stranska R, Schuurman R, Nienhuis E et al.: Survey of acyclovir-resistant herpes simplex virus in The Netherlands: prevalence and characterization. J. Clin. Virol. 32(1), 7-18 (2005).
29. Czartoski T, Liu C, Koelle DM, Schmechel S, Kalus A, Wald A: Fulminant, acyclovir-resistant, herpes simplex virus type 2 hepatitis in an immunocompetent woman. J. Clin. Microbiol. 44(4), 1584-1586 (2006).
30. Schinazi RF, del Bene V, Scott RT, Dudley Thorpe JB: Characterization of acyclovir-resistant and -sensitive herpes simplex viruses isolated from a patient with an acquired immune deficiency. J. Antimicrob. Chemother. 18(Suppl. B), 127-134 (1986).
31. Mott KR, Bresee CJ, Allen SJ, BenMohamed L, Wechsler SL, Ghiasi H: Level of herpes simplex virus type 1 latency correlates with severity of corneal scarring and exhaustion of CD8+ T cells in trigeminal ganglia of latently infected mice. J. Virol. 83(5), 2246-2254 (2009).
32. Mott KR, Chentoufi AA, Carpenter D, BenMohamed L, Wechsler S, Ghiasi H: A glycoprotein K (gK) CD8+ T-cell epitope of herpes simplex virus types 1 and 2 increases ocular virus replication and pathogenicity. Invest. Ophthalmol. Vis. Sci. doi: 10.1167/iovs.08-2957 (2009) (Epub ahead of print).
33. Zhang X, Chentoufi AA, Dasgupta G et al.: A genital tract peptide epitope vaccine targeting TLR-2 efficiently induces local and systemic CD8+ T cells and protects against herpes simplex virus type 2 challenge. Mucosal Immunol. 2(2), 129-143 (2009).